HC Wainwright Reiterates “Buy” Rating for MiNK Therapeutics (NASDAQ:INKT)

MiNK Therapeutics (NASDAQ:INKT)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They presently have a $9.00 target price on the stock.

MiNK Therapeutics Price Performance

Shares of NASDAQ INKT opened at $0.68 on Wednesday. The firm’s 50 day simple moving average is $0.78 and its 200-day simple moving average is $0.90. MiNK Therapeutics has a 12 month low of $0.57 and a 12 month high of $1.90.

MiNK Therapeutics (NASDAQ:INKT) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.03. Equities analysts predict that MiNK Therapeutics will post -0.33 EPS for the current fiscal year.

Hedge Funds Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Renaissance Technologies LLC lifted its holdings in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 127,841 shares of the company’s stock after buying an additional 22,613 shares during the quarter. Renaissance Technologies LLC owned approximately 0.37% of MiNK Therapeutics worth $121,000 as of its most recent SEC filing. 2.87% of the stock is owned by hedge funds and other institutional investors.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.